Open AccessIslet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation Blockade
Author(s) -
Andrew M. Posselt,
Gregory L. Szot,
Lynda Frassetto,
Umesh Masharani,
Mehdi Tavakol,
Raj M. Amin,
Joan McElroy,
Marissa Ramos,
Robert K. Kerlan,
Lawrence Fong,
Flavio Vincenti,
Jeffrey A. Bluestone,
Peter Stock
Publication year - 2010
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181fe1377
Subject(s) - medicine , calcineurin , immunosuppression , belatacept , islet , daclizumab , transplantation , insulin , type 1 diabetes , diabetes mellitus , immunology , tacrolimus , endocrinology , kidney transplantation , kidney transplant
The applicability of islet transplantation as treatment for type 1 diabetes is limited by long-term graft dysfunction, immunosuppressive drug toxicity, need for multiple donors, and increased risk of allosensitization. We describe two immunosuppressive regimens based on the costimulation blocker belatacept (BELA) or the antileukocyte functional antigen-1 antibody efalizumab (EFA), which permit long-term islet allograft survival and address some of these concerns.